Leukemia combo shot and pill shows promise in early trial
NCT ID NCT07178912
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Participants may have newly diagnosed or relapsed leukemia. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blinatumomab and olverembatinib
- What this could lead to
- If successful, this combination could offer a new, more convenient treatment option for people with Ph-positive ALL, potentially improving disease control without needing IV infusions.
- What could go wrong
- This is a small, early-phase (Phase 2) study with only 60 participants. The combination may cause side effects or not work better than existing treatments. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLINATUMOMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to improve remission in older leukemia patients
- Real-World watch on ph+ leukemia treatments aims to uncover best paths to remission
- Engineered immune cells take aim at tough childhood leukemia
- Double strike: engineered immune cells and targeted pill take on tough leukemia
- New drug aims to keep leukemia in remission after transplant
- Could natural immune cells help fight leukemia drug resistance?